专利检索 ap:("EGE UNIVERSITESI" OR "MEFAR ILAC SAN. A.S.") AND inv:"Ozlem YESIL" 第 1 页

1.

发明公开
DEVELOPMENT OF AN INNOVATIVE INHALATION FORMULATION OF NAFAMOSTAT MESYLATE FOR THE MANAGEMENT OF COVID-19 审中-公开

公开(公告)号：US20240293350A1

公开(公告)日：2024-09-05

申请号：US18258857

申请日：2021-12-22

申请人： EGE UNIVERSITESI , MEFAR ILAC SAN. A.S.

发明人： Kambez HAJIPOURAN BENAM , Ozlem YESIL , Tuncay GOKSEL , Mine OZYAZICI , Mesut ARICI , Aysu YURDASIPER , Ozlem GOKSEL

IPC分类号： A61K31/245 , A61K9/00 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/26

CPC分类号： A61K31/245 , A61K9/0078 , A61K47/12 , A61K47/183 , A61K47/20 , A61K47/26

摘要： The development of innovative inhalation formulations and preparation methods are provided to be used in the prophylaxis of COVID-19-related mortality from a broad-spectrum serine protease inhibitor NM, which has a potent anti-viral and anti-inflammatory potential. A drug for the infection treatment of SARS-COV-2, Influenza A, Influenza B and NL63 viruses includes the drug substance Nafamostat mesylate, which is a serine protease inhibitor in its inhalation form.